Zhongguancun announced that its subsidiary, Beijing Huasu Pharmaceutical, recently received a “Notice of Acceptance” issued by the State Drug Administration, and its marketing license application for trazodone hydrochloride sustained-release tablets was accepted. The drug is suitable for treating depression with or without symptoms of anxiety. As of the announcement disclosure date, the project has invested a total of 5.35 million yuan in research and development costs. If successfully approved, it will increase the competitiveness of the enterprise and the market, and have a positive impact on the company's operating performance.

Zhongguancun announced that its subsidiary, Beijing Huasu Pharmaceutical, recently received a “Notice of Acceptance” issued by the State Drug Administration, and its marketing license application for trazodone hydrochloride sustained-release tablets was accepted. The drug is suitable for treating depression with or without symptoms of anxiety. As of the announcement disclosure date, the project has invested a total of 5.35 million yuan in research and development costs. If successfully approved, it will increase the competitiveness of the enterprise and the market, and have a positive impact on the company's operating performance.